Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Invyncible vs MyFastRx

Invyncible
Graded #303

Lower grade

vs+6.599999999999994
MyFastRx
Graded #161

Higher grade

The verdict

MyFastRx takes it — 67.6/100 to 61/100.

MyFastRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyFastRx is a cash-pay compounded-GLP-1 platform built around fast approval and discounted multi-month bundles.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMyFastRx +21
55
76
Dose & formulationMyFastRx +8
64
72
Clinical oversightInvyncible +4
70
66
Labs & monitoringEven
52
52
FulfillmentMyFastRx +18
65
83
Contract termsInvyncible +20
61
41
Invyncible · left barMyFastRx · right bar

The numbers

MetricInvyncibleMyFastRx
WeighScore61/10067.6/100
GradeCC
Scorecard rank#303#161
Semaglutide$192/mo (0.5 mg dose, compounded)$169/mo
Tirzepatide$210/mo (compounded)$249/mo
Coverage40 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Invyncible

Graded #303 · C

Strengths

  • Corporate parent disclosed (Nationwide Telemedicine, LLC) — better than most competitors hiding behind trade names
  • Physical corporate address published (St. Petersburg, FL)
  • LegitScript verification seal displayed
  • No long-term commitment required
  • Offers both semaglutide and tirzepatide programs

Where it loses points

  • Pricing not disclosed on the public site — fully gated behind signup
  • Drug forms (compounded vs brand, injection vs oral) not disclosed
  • 503A vs 503B designation not specified
  • Pharmacy partner not named
  • States served not listed publicly
MyFastRx

Graded #161 · C

Strengths

  • Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
  • LegitScript certified
  • All doses priced the same — no cost escalation as you titrate up
  • First-month promo discount lowers the trial barrier

Where it loses points

  • States served not disclosed — only 'multiple states' / 'licensed U.S. providers'
  • Corporate address and medical director not published
  • Pharmacy partner not named — only 'state-licensed pharmacies'
  • Cash-pay only — no insurance billing
  • Bundle savings require a large upfront commitment (12 months billed at once)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard